Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Reply: Benefits of Empagliflozin Beyond Enhancing Myocardial Energetics?

Santos-Gallego CG, Garcia-Ropero A, Badimon J.

J Am Coll Cardiol. 2019 Aug 13;74(6):826. doi: 10.1016/j.jacc.2019.06.017. No abstract available.

PMID:
31395140
2.

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance.

García-Ropero Á, Vargas-Delgado AP, Santos-Gallego CG, Badimon JJ.

Int J Mol Sci. 2019 Jul 4;20(13). pii: E3289. doi: 10.3390/ijms20133289. Review.

3.

LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Sabatel-Pérez F, García-Ropero A, Santos-Gallego CG, Urooj Zafar M, Badimón JJ.

Drugs Today (Barc). 2019 May;55(5):329-344. doi: 10.1358/dot.2019.55.5.2976501. Review.

PMID:
31131843
4.

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.

Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, Fuster V, Badimon JJ.

J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944. doi: 10.1016/j.jacc.2019.01.056.

PMID:
30999996
5.

Dual versus triple antithrombotic therapy: is there a role for direct oral anticoagulants in arterial thrombosis?

Garcia-Ropero A, Santos-Gallego CG, Zafar MU, Badimon JJ.

Drugs Today (Barc). 2019 Mar;55(3):197-214. doi: 10.1358/dot.2019.55.3.2903216. Review.

PMID:
30938374
6.

SGLT receptors and myocardial ischaemia-reperfusion injury: inhibition of SGLT-1, SGLT-2, or both?

Garcia-Ropero A, Santos-Gallego CG, Badimon JJ.

Cardiovasc Res. 2019 Sep 1;115(11):1572-1573. doi: 10.1093/cvr/cvz077. No abstract available.

PMID:
30873553
7.

Metabolism of the failing heart and the impact of SGLT2 inhibitors.

Garcia-Ropero A, Santos-Gallego CG, Zafar MU, Badimon JJ.

Expert Opin Drug Metab Toxicol. 2019 Apr;15(4):275-285. doi: 10.1080/17425255.2019.1588886. Epub 2019 Mar 11. Review.

PMID:
30822172
8.

Proceedings of the 3rd annual Acute Cardiac Unloading and REcovery (A-CURE) symposium.

Chandrasekaran U, Burkhoff D, Ishikawa K, Swain L, Sunagawa K, Møller J, Santos-Gallego C, Annamalai S, Udelson J, Westenfeld R, Kapur N, Qiao X, Wiora J, Schäfer A, Bernhardt A, Kochar A, Kloner R, Faraz H.

BMC Cardiovasc Disord. 2019 Feb 7;19(Suppl 2):27. doi: 10.1186/s12872-019-1000-z. No abstract available.

9.

Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?

Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, Fergus I, Abascal V, Moreno P, Atallah-Lajam F, Tamler R, Lala A, Sanz J, Fuster V, Badimon JJ.

Cardiovasc Drugs Ther. 2019 Feb;33(1):87-95. doi: 10.1007/s10557-018-06850-0.

PMID:
30675708
10.

Spark That Lights the Fire: Infection Triggers Cardiovascular Events.

Santos-Gallego CG, García-Ropero Á, Badimon JJ.

J Am Heart Assoc. 2018 Nov 20;7(22):e011175. doi: 10.1161/JAHA.118.011175.

11.

High-Density Lipoprotein-Targeted Therapies-Not Dead Yet.

Garcia-Ropero A, Santos-Gallego CG, Badimon JJ.

JAMA Cardiol. 2018 Dec 1;3(12):1254-1255. doi: 10.1001/jamacardio.2018.3962. No abstract available.

PMID:
30484828
12.

The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.

Garcia-Ropero A, Badimon JJ, Santos-Gallego CG.

Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1287-1302. doi: 10.1080/17425255.2018.1551877. Epub 2018 Nov 29. Review.

PMID:
30463454
13.

T2 magnetic resonance mapping: The key to find the 'Brahmastra' against atherosclerosis?

Kumar A, Santos-Gallego CG, Chatzizisis YS.

Atherosclerosis. 2018 Dec;279:95-96. doi: 10.1016/j.atherosclerosis.2018.10.021. Epub 2018 Oct 19. No abstract available.

PMID:
30401492
14.

Badimon Perfusion Chamber: An Ex Vivo Model of Thrombosis.

Zafar MU, Santos-Gallego CG, Badimon L, Badimon JJ.

Methods Mol Biol. 2018;1816:161-171. doi: 10.1007/978-1-4939-8597-5_12.

PMID:
29987818
15.

Modulatory Role of Pulsatility on von Willebrand Factor: Implications for Mechanical Circulatory Support-Associated Bleeding.

Badimon JJ, Santos-Gallego CG.

J Am Coll Cardiol. 2018 May 15;71(19):2119-2121. doi: 10.1016/j.jacc.2018.02.074. No abstract available.

16.

Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?

Flores E, Santos-Gallego CG, Diaz-Mejía N, Badimon JJ.

Cardiovasc Drugs Ther. 2018 Apr;32(2):213-222. doi: 10.1007/s10557-018-6786-x. Review.

PMID:
29679303
17.

Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions.

Zafar MU, Santos-Gallego CG, Smith DA, Halperin JL, Badimon JJ.

Atherosclerosis. 2017 Nov;266:81-86. doi: 10.1016/j.atherosclerosis.2017.09.029. Epub 2017 Sep 28.

PMID:
28992468
18.

Non-cardiac sarcoid actually affects the heart by reducing coronary flow reserve.

Santos-Gallego CG, Weiss AJ, Sanz J.

Atherosclerosis. 2017 Sep;264:74-76. doi: 10.1016/j.atherosclerosis.2017.07.006. Epub 2017 Jul 8. No abstract available.

PMID:
28774485
19.

Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery.

Bartko PE, Wiedemann D, Schrutka L, Binder C, Santos-Gallego CG, Zuckermann A, Steinlechner B, Koinig H, Heinz G, Niessner A, Zimpfer D, Laufer G, Lang IM, Distelmaier K, Goliasch G.

J Am Heart Assoc. 2017 Jul 28;6(8). pii: e005455. doi: 10.1161/JAHA.116.005455.

20.

Echocardiographic and hemodynamic assessment for predicting early clinical events in severe acute mitral regurgitation.

Watanabe S, Fish K, Bonnet G, Santos-Gallego CG, Leonardson L, Hajjar RJ, Ishikawa K.

Int J Cardiovasc Imaging. 2018 Feb;34(2):171-175. doi: 10.1007/s10554-017-1215-y. Epub 2017 Jul 22.

21.

Myocardial infarction caused by surgery: Blame inflammation not the surgeon.

Santos-Gallego CG, Wallert M, Peter K.

Atherosclerosis. 2016 Dec;255:113-116. doi: 10.1016/j.atherosclerosis.2016.08.044. Epub 2016 Sep 1. No abstract available.

PMID:
27616135
22.

Niacin is still beneficial. Implications from an updated meta-regression analysis.

Siniawski D, Santos-Gallego CG, Badimon JJ, Masson WM.

Acta Cardiol. 2016 Aug;71(4):463-72. doi: 10.2143/AC.71.4.3159701. No abstract available.

PMID:
27594363
23.

MafB and the role of macrophage apoptosis in atherosclerosis: A time to kill, a time to heal.

Santos-Gallego CG.

Atherosclerosis. 2016 Sep;252:194-196. doi: 10.1016/j.atherosclerosis.2016.06.026. Epub 2016 Jun 16. No abstract available.

PMID:
27338219
24.

Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.

Aguero J, Ishikawa K, Hadri L, Santos-Gallego CG, Fish KM, Kohlbrenner E, Hammoudi N, Kho C, Lee A, Ibáñez B, García-Alvarez A, Zsebo K, Maron BA, Plataki M, Fuster V, Leopold JA, Hajjar RJ.

J Am Coll Cardiol. 2016 May 3;67(17):2032-46. doi: 10.1016/j.jacc.2016.02.049.

25.

Cadmium and atherosclerosis: Heavy metal or singing the blues?

Santos-Gallego CG, Jialal I.

Atherosclerosis. 2016 Jun;249:230-2. doi: 10.1016/j.atherosclerosis.2016.01.041. Epub 2016 Feb 4. No abstract available.

PMID:
27012656
26.

Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion.

Santos-Gallego CG, Vahl TP, Goliasch G, Picatoste B, Arias T, Ishikawa K, Njerve IU, Sanz J, Narula J, Sengupta PP, Hajjar RJ, Fuster V, Badimon JJ.

Circulation. 2016 Mar 8;133(10):954-66. doi: 10.1161/CIRCULATIONAHA.115.012427. Epub 2016 Jan 29.

PMID:
26826180
27.

Cyclosporine before PCI in Acute Myocardial Infarction.

Santos-Gallego CG, Badimon JJ.

N Engl J Med. 2016 Jan 7;374(1):88. doi: 10.1056/NEJMc1514192. No abstract available.

PMID:
26736000
28.

Cardiac Complications After Community-Acquired Pneumonia.

Santos-Gallego CG, Badimon JJ.

Am J Cardiol. 2016 Jan 15;117(2):310. doi: 10.1016/j.amjcard.2015.10.003. Epub 2015 Oct 23. No abstract available.

PMID:
26552508
29.

HDL Dysfunction: Is the Answer in the Sphinx's Riddle?

Badimon JJ, Santos-Gallego CG.

J Am Coll Cardiol. 2015 Sep 29;66(13):1486-8. doi: 10.1016/j.jacc.2015.08.008. No abstract available.

30.

HDL: Quality or quantity?

Santos-Gallego CG.

Atherosclerosis. 2015 Nov;243(1):121-3. doi: 10.1016/j.atherosclerosis.2015.08.027. Epub 2015 Aug 29. No abstract available.

PMID:
26378719
31.

Legacy of blood: does prasugrel inhibit megakaryocytes and do juvenile platelets inherit this inhibition?

Santos-Gallego CG.

Haematologica. 2015 Sep;100(9):1103-5. doi: 10.3324/haematol.2015.132134. No abstract available.

32.

Catheter-based Renal Denervation as a Treatment for Pulmonary Hypertension: Hope or Hype?

Santos-Gallego CG, Badimón JJ.

Rev Esp Cardiol (Engl Ed). 2015 Jul;68(7):551-3. doi: 10.1016/j.rec.2015.03.007. Epub 2015 May 29. No abstract available.

PMID:
26032026
33.

Increased stiffness is the major early abnormality in a pig model of severe aortic stenosis and predisposes to congestive heart failure in the absence of systolic dysfunction.

Ishikawa K, Aguero J, Oh JG, Hammoudi N, Fish LA, Leonardson L, Picatoste B, Santos-Gallego CG, Fish KM, Hajjar RJ.

J Am Heart Assoc. 2015 May 20;4(5). pii: e001925. doi: 10.1161/JAHA.115.001925.

34.

Reply: platelets interplay between pneumonia and cardiovascular events: establishing a link?

Santos-Gallego CG, Badimon J.

J Am Coll Cardiol. 2015 Apr 14;65(14):1490-1. doi: 10.1016/j.jacc.2014.12.058. No abstract available.

35.

Reply to "Letter to the editor: Characterizing preclinical model of ischemic heart failure: difference between LAD and LCx infarctions".

Ishikawa K, Aguero J, Tilemann L, Ladage D, Hammoudi N, Kawase Y, Santos-Gallego CG, Fish K, Levine RA, Hajjar RJ.

Am J Physiol Heart Circ Physiol. 2015 Feb 15;308(4):H365-6. doi: 10.1152/ajpheart.00855.2014. No abstract available.

36.

The sum of two evils: pneumonia and myocardial infarction: is platelet activation the missing link?

Santos-Gallego CG, Badimon JJ.

J Am Coll Cardiol. 2014 Nov 4;64(18):1926-8. doi: 10.1016/j.jacc.2014.08.023. Epub 2014 Oct 27. No abstract available.

37.

Beginning to understand high-density lipoproteins.

Santos-Gallego CG, Badimon JJ, Rosenson RS.

Endocrinol Metab Clin North Am. 2014 Dec;43(4):913-47. doi: 10.1016/j.ecl.2014.08.001. Review.

PMID:
25432389
38.

Niacin for reduction of cardiovascular risk.

Santos-Gallego CG, Badimon J.

N Engl J Med. 2014 Nov 13;371(20):1943. doi: 10.1056/NEJMc1411240. No abstract available.

PMID:
25390753
39.

Characterizing preclinical models of ischemic heart failure: differences between LAD and LCx infarctions.

Ishikawa K, Aguero J, Tilemann L, Ladage D, Hammoudi N, Kawase Y, Santos-Gallego CG, Fish K, Levine RA, Hajjar RJ.

Am J Physiol Heart Circ Physiol. 2014 Nov 15;307(10):H1478-86. doi: 10.1152/ajpheart.00797.2013. Epub 2014 Sep 12.

40.

Role of HDL in those with diabetes.

Santos-Gallego CG, Rosenson RS.

Curr Cardiol Rep. 2014 Sep;16(9):512. Review.

PMID:
25199216
41.

Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model.

Aguero J, Ishikawa K, Hadri L, Santos-Gallego C, Fish K, Hammoudi N, Chaanine A, Torquato S, Naim C, Ibanez B, Pereda D, García-Alvarez A, Fuster V, Sengupta PP, Leopold JA, Hajjar RJ.

Am J Physiol Heart Circ Physiol. 2014 Oct 15;307(8):H1204-15. doi: 10.1152/ajpheart.00246.2014. Epub 2014 Aug 22.

42.

Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure.

Ishikawa K, Fish KM, Tilemann L, Rapti K, Aguero J, Santos-Gallego CG, Lee A, Karakikes I, Xie C, Akar FG, Shimada YJ, Gwathmey JK, Asokan A, McPhee S, Samulski J, Samulski RJ, Sigg DC, Weber T, Kranias EG, Hajjar RJ.

Mol Ther. 2014 Dec;22(12):2038-45. doi: 10.1038/mt.2014.127. Epub 2014 Jul 15.

43.

Role of HDL in those with diabetes.

Santos-Gallego CG, Rosenson RS.

Curr Cardiol Rep. 2014 Aug;16(8):512. doi: 10.1007/s11886-014-0512-5. Review.

PMID:
24950673
44.

Pathophysiology of acute coronary syndrome.

Santos-Gallego CG, Picatoste B, Badimón JJ.

Curr Atheroscler Rep. 2014 Apr;16(4):401. doi: 10.1007/s11883-014-0401-9. Review.

PMID:
24504549
45.

SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure.

Tilemann L, Lee A, Ishikawa K, Aguero J, Rapti K, Santos-Gallego C, Kohlbrenner E, Fish KM, Kho C, Hajjar RJ.

Sci Transl Med. 2013 Nov 13;5(211):211ra159. doi: 10.1126/scitranslmed.3006487.

46.

Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation.

Zafar MU, Santos-Gallego C, Vorchheimer DA, Viles-Gonzalez JF, Elmariah S, Giannarelli C, Sartori S, Small DS, Jakubowski JA, Fuster V, Badimon JJ.

J Thromb Haemost. 2013 Jan;11(1):100-6. doi: 10.1111/jth.12058.

47.

Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term.

Giannarelli C, Cimmino G, Ibanez B, Chiesa G, Garcia-Prieto J, Santos-Gallego CG, Alique-Aguilar M, Fuster V, Sirtori C, Badimon JJ.

Thromb Haemost. 2012 Dec;108(6):1246-8. doi: 10.1160/TH12-08-0556. Epub 2012 Oct 23. No abstract available.

PMID:
23093000
48.

Free mitral regurgitation due to asynchrony and improvement with cardiac resynchronization.

Briongos-Figuero S, Santos-Gallego CG, Moya Mur JL.

J Am Coll Cardiol. 2012 Jul 17;60(3):232. doi: 10.1016/j.jacc.2011.12.056. No abstract available.

49.

High-density lipoprotein and cardiovascular risk reduction: promises and realities.

Santos-Gallego CG, Badimón JJ.

Rev Esp Cardiol (Engl Ed). 2012 Apr;65(4):305-8. doi: 10.1016/j.recesp.2011.10.021. Epub 2012 Feb 14. No abstract available.

PMID:
22336107
50.

Assessing left ventricular systolic dysfunction after myocardial infarction: are ejection fraction and dP/dt(max) complementary or redundant?

Ishikawa K, Chemaly ER, Tilemann L, Fish K, Ladage D, Aguero J, Vahl T, Santos-Gallego C, Kawase Y, Hajjar RJ.

Am J Physiol Heart Circ Physiol. 2012 Apr 1;302(7):H1423-8. doi: 10.1152/ajpheart.01211.2011. Epub 2012 Feb 3.

Supplemental Content

Loading ...
Support Center